Timeline
More in Healthcare
PureTech's Seaport advances GlyphAgo into Phase 2 after positive Phase 1 multiple‑dose data
"We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo," said Daphne Zohar, Co‑Founder and Chief Executive Officer of Seaport Therapeutics.